Enzalutamide in European and North American men participating in the AFFIRM trial-Reference-Cited by-同舟云学术

Enzalutamide in European and North American men participating in the AFFIRM trial

Published:2014-10-23 Issue:1 Volume:115 Page:41-49
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Merseburger Axel S.¹,Scher Howard I.²,Bellmunt Joaquim³,Miller Kurt⁴,Mulders Peter F.A.⁵,Stenzl Arnulf⁶,Sternberg Cora N.⁷,Fizazi Karim⁸,Hirmand Mohammad⁹,Franks Billy¹⁰,Haas Gabriel P.¹⁰,de Bono Johann¹¹,de Wit Ronald¹²

Affiliation:

1. Medizinische Hochschule Hannover; Hannover Germany

2. Memorial Sloan-Kettering Cancer Center; New York NY USA

3. Dana-Farber Cancer Institute; Harvard Medical School; Boston MA USA

4. Charité - Universitätsmedizin Berlin; Berlin Germany

5. Radboud University Nijmegen Medical Centre; Nijmegen The Netherlands

6. Universitätsklinikum Tübingen; Tübingen Germany

7. San Camillo - Forlanini Hospitals; Rome Italy

8. Institut Gustave Roussy; University of Paris Sud; Villejuif France

9. Medivation, Inc.; San Francisco CA USA

10. Astellas Scientific and Medical Affairs, Inc.; Northbrook IL USA

11. Institute of Cancer Research and Royal Marsden NHS Foundation Trust; Sutton UK

12. Erasmus University Medical Center; Rotterdam The Netherlands

Funder

Astellas Pharma, Inc and Medivation, Inc

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.12898/fullpdf

Reference29 articles.

1. Perspectives on treatment of metastatic castration-resistant prostate cancer;Merseburger;Oncologist,2013

2. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis;Scher;J Clin Oncol,2005

3. [Pathophysiology and therapy of castration-resistant prostate cancer];Merseburger;Urologe A,2013

4. Targeting continued androgen receptor signaling in prostate cancer;Massard;Clin Cancer Res,2011

5. Castration-resistant prostate cancer: where we stand in 2013 and what urologists should know;Heidenreich;Eur Urol,2013

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis;European Urology Focus;2021-04

2. Efficacy and Safety of Non-Steroidal Anti-Androgens in Patients with Metastatic Prostate Cancer: Meta-Analysis of Randomized Controlled Trials;Reviews on Recent Clinical Trials;2020-02-14

3. The importance of antiandrogen in prostate cancer treatment;Annals of Translational Medicine;2019-12

4. ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis;Cancer Letters;2018-12

5. Second-line therapy in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel: A systematic review of nine randomized controlled trials;Seminars in Oncology;2017-10